Synergy Pharmaceuticals

Bespreek hier de kleinere aandelen van de beurs in New York
Plaats reactie
Lampi
Forum gebruiker
Forum gebruiker
Berichten: 145
Lid geworden op: 21 Jun 2017 19:29
Likes: 24
Contact:

Re: Synergy Pharmaceuticals

Berichtdoor Lampi » 07 Okt 2017 09:23

hey, rustig forum hier, eerste maal ingestapt voor klein bedrag vorige maand, dan tweede pakketje bijgekocht op bijna bottom. beklaag me nu al dat ik geen grotere positive gonemen heb, met de laatste presentative is de 5 a 6 dollar bijna een zekerheid!


amazingless
Forum actieveling
Forum actieveling
Berichten: 312
Lid geworden op: 02 Jul 2012 16:05
Likes: 27
Contact:

Re: Synergy Pharmaceuticals

Berichtdoor amazingless » 13 Okt 2017 09:16

Synergy Pharmaceuticals Inc. (NASDAQ:SGYP) today announced that the company will present two abstracts, including Phase 3 studies evaluating TRULANCE® (plecanatide) for the treatment of adults with irritable bowel syndrome with constipation (IBS-C) at the World Congress of Gastroenterology (WCOG) at American College of Gastroenterology (ACG), Oct. 13-18, 2017,  orlando fl
Laatst gewijzigd door amazingless op 13 Okt 2017 09:19, 1 keer totaal gewijzigd.
exmar/pfizer,Fibrocel,Generalmoly,Caratherapeutics,Freeport,Tshrombo,MDx,Petrobras,ablynx,nyrstar,shakeshack,sarepta,,biocartis,teva,,echo -&synergy therapeutics,catalyst bioscience,fortress bio

Lampi
Forum gebruiker
Forum gebruiker
Berichten: 145
Lid geworden op: 21 Jun 2017 19:29
Likes: 24
Contact:

Re: Synergy Pharmaceuticals

Berichtdoor Lampi » 13 Okt 2017 09:17

amazingless schreef:Synergy Pharmaceuticals Inc. (NASDAQ:SGYP) today announced that the company will present two abstracts, including Phase 3 studies evaluating TRULANCE® (plecanatide) for the treatment of adults with irritable bowel syndrome with constipation (IBS-C) at the World Congress of Gastroenterology (WCOG) at American College of Gastroenterology (ACG), Oct. 13-18, 2017, 

zat ik op te wachten - nu gaan we terug naar boven, geen twijfel!

Lampi
Forum gebruiker
Forum gebruiker
Berichten: 145
Lid geworden op: 21 Jun 2017 19:29
Likes: 24
Contact:

Re: Synergy Pharmaceuticals

Berichtdoor Lampi » 13 Okt 2017 09:25

Lampi schreef:
amazingless schreef:Synergy Pharmaceuticals Inc. (NASDAQ:SGYP) today announced that the company will present two abstracts, including Phase 3 studies evaluating TRULANCE® (plecanatide) for the treatment of adults with irritable bowel syndrome with constipation (IBS-C) at the World Congress of Gastroenterology (WCOG) at American College of Gastroenterology (ACG), Oct. 13-18, 2017, 

zat ik op te wachten - nu gaan we terug naar boven, geen twijfel!

dacht al dat ik de enige was met dit aandeel :D

amazingless
Forum actieveling
Forum actieveling
Berichten: 312
Lid geworden op: 02 Jul 2012 16:05
Likes: 27
Contact:

Re: Synergy Pharmaceuticals

Berichtdoor amazingless » 13 Okt 2017 12:14

Recent insider trends for Synergy Pharmaceuticals Inc. (NASDAQ:SGYP) have caught the attention of investors. Insider activity is often a strong indicator of future performance in a stock, and if the data on SGYP is anything to go by, investors should pay attention.

Institutions own 71.50% of Synergy Pharmaceuticals Inc. (SGYP)’s shares. The total value of these holdings, in millions, is $539. Among active positions in the latest quarter, 90 holders increased their positions by a total of 19.26 million shares, 67 holders decreased the positions by a total of 10.2 million shares, and 28 holders held their positions. This works out to a net increase in ownership of 9.05 million shares, and suggests that institutions are feeling bullish about the stock.

Among new and sold out positions, 24 holders initiated new positions by a total of 6.45 million shares and 39 holders exited their positions by a total of 4.62 million shares. This nets out to an increase of 1.83 million shares and is a bullish sign for SGYP.

art verscheen 20 hours ago (volgens google)
exmar/pfizer,Fibrocel,Generalmoly,Caratherapeutics,Freeport,Tshrombo,MDx,Petrobras,ablynx,nyrstar,shakeshack,sarepta,,biocartis,teva,,echo -&synergy therapeutics,catalyst bioscience,fortress bio

amazingless
Forum actieveling
Forum actieveling
Berichten: 312
Lid geworden op: 02 Jul 2012 16:05
Likes: 27
Contact:

Re: Synergy Pharmaceuticals

Berichtdoor amazingless » 17 Okt 2017 07:07

Analysis  

John Engle

Not A Falling Knife: Synergy Pharmaceuticals' Drop Makes For A Great Buy

Oct. 16, 2017 3:58 PM • SGYP

Summary

Synergy’s share price fell nearly 7% on Friday, due in part to positive results for a potential competitor drug in the irritable bowel syndrome indication.The slow launch of Trulance continues to weigh on the share price, but improving sales processes are taking effect.With approval of a new indication on the horizon and a data presentation this week, Synergy looks significantly undervalued.

gisteren nog pakket ingeslagen aan $3.20. Had beter iets langer gewacht. gemiddelde nu $3.73
exmar/pfizer,Fibrocel,Generalmoly,Caratherapeutics,Freeport,Tshrombo,MDx,Petrobras,ablynx,nyrstar,shakeshack,sarepta,,biocartis,teva,,echo -&synergy therapeutics,catalyst bioscience,fortress bio

amazingless
Forum actieveling
Forum actieveling
Berichten: 312
Lid geworden op: 02 Jul 2012 16:05
Likes: 27
Contact:

Re: Synergy Pharmaceuticals

Berichtdoor amazingless » 17 Okt 2017 07:11

Home  Insiders And Owners

INSIDERS AND OWNERSINSTITUTIONAL INVESTORS NOW HAVE $534 MILLION STAKE IN SYNERGY PHARMACEUTICALS INC. (SGYP)

October 16, 2017

    

Synergy Pharmaceuticals Inc. (NASDAQ:SGYP) marched up 20.7% compared to a 52-week low price of $2.56. The shares were last seen trading -6.93% lower, taking the closing price at $3.09 on Oct. 13, 2017. At recent session, the prices were hovering between $3.08 and $3.38. This company shares are 175.08% off its target price of $8.5 and the current market capitalization stands at $695.06M. The recent change has given its price a 2.24% lead over SMA 50 and -56.78% deficit over its 52-week high. The stock witnessed 17.94% gains, -28.97% declines and -30.09% declines for the 1-month, 3-month and 6-month period, respectively. To measure price-variation, we found SGYP’s volatility during a week at 5.81% and during a month it has been found around 5.65%.

Synergy Pharmaceuticals Inc. (SGYP) Top Holders

Institutional investors currently hold around $534 million or 73.8% in SGYP stock. Look at its top three institutional owners. Paulson & Co. Inc. owns $79.97 million in Synergy Pharmaceuticals Inc., which represents roughly 11.51% of the company’s market cap and approximately 14.98% of the institutional ownership. Similar statistics are true for the second largest owner, Orbimed Advisors Llc, which owns 21,153,343 shares of the stock are valued at $70.23 million. The third largest holder is Blackrock Inc., which currently holds $65.86 million worth of this stock and that ownership represents nearly 9.47% of its market capitalization.
exmar/pfizer,Fibrocel,Generalmoly,Caratherapeutics,Freeport,Tshrombo,MDx,Petrobras,ablynx,nyrstar,shakeshack,sarepta,,biocartis,teva,,echo -&synergy therapeutics,catalyst bioscience,fortress bio

amazingless
Forum actieveling
Forum actieveling
Berichten: 312
Lid geworden op: 02 Jul 2012 16:05
Likes: 27
Contact:

Re: Synergy Pharmaceuticals

Berichtdoor amazingless » 17 Okt 2017 08:03

Out Fox The $treet: October 17, 2017

Stocks to watch on Tuesday:

Glu Mobile (GLUU) - mobile-game developer closed near the low of the day with a minimal $0.09 gain. Stock probably needs to consolidate the gains at this point, but Glu Mobile remains cheap compared to the opportunity of the existing games and the potential of a Taylor Swift app. 

Synergy Pharma (SGYP) - predicted last week that the biotech would pull back. Just below $3, Synergy Pharma closes the gap and becomes a buy again. The market misses the Trulance sales and got too focused on the debt financing that remains a long-term positive. 

Twitter (TWTR) - the power of Twitter is proven every day. Engagement growth will lead to higher ad sales in 2018. 

Click on the Sign in/Sign up button in the top right corner to join for free to comment on your stock moves for tomorrow. 
exmar/pfizer,Fibrocel,Generalmoly,Caratherapeutics,Freeport,Tshrombo,MDx,Petrobras,ablynx,nyrstar,shakeshack,sarepta,,biocartis,teva,,echo -&synergy therapeutics,catalyst bioscience,fortress bio

JoachimDM
Forum verkenner
Forum verkenner
Berichten: 45
Lid geworden op: 25 Feb 2016 12:08
Likes: 14
Contact:

Re: Synergy Pharmaceuticals

Berichtdoor JoachimDM » 27 Okt 2017 09:11

Synergy, een tijdje geleden. Ik ben reeds lange tijd uitgestapt, maar de laatste tijd volg ik dit aandeel terug. Er zit heel wat potentie in dit aandeel. De Trulance verkopen kunnen en zullen nog heel wat stijgen, zeker als IBS-C ook goedgekeurd wordt,met Dolcanatide hebben ze ook nog een heel grote troef achter de hand. Het enige wat mij afschrikt is de hoge kosten van de sales momenteel.

https://seekingalpha.com/article/4116151-celgenes-gedminus-0301-failure-offers-peek-value-synergys-dolcanatide

https://seekingalpha.com/article/4115743-synergy-pharmaceuticals-opportunity-irritable-markets

amazingless
Forum actieveling
Forum actieveling
Berichten: 312
Lid geworden op: 02 Jul 2012 16:05
Likes: 27
Contact:

Re: Synergy Pharmaceuticals

Berichtdoor amazingless » 10 Nov 2017 08:17

Third Quarter 2017 and Recent Highlights

TRULANCE CIC Launch Update (as of September 30, 2017)

Demand and prescriber growth (per QuintilesIMS)

More than 25,000 prescriptions were filled in the third quarter of 2017, up 105% over the prior quarter, with more than 37,700 prescriptions filled since launch in March.Over 7,000 healthcare professionals had prescribed TRULANCE, an 87% increase over the second quarter.Half of TRULANCE prescriptions continued to come from patients who were new to branded prescription treatment.

Coverage Progress

Approximately 84% of lives covered by the largest commercial plans in the U.S. had TRULANCE coverage, with up to 67% having unrestricted access.Over 40% of lives covered by the largest Medicare Part D and Managed Medicaid plans in the U.S. had TRULANCE on formulary.Based on ongoing discussions with payers, Synergy expects most remaining new-to-market (NTM) blocks to be lifted in the first half of 2018 and for TRULANCE to gain even more favorable access across commercial, Medicare Part D and Managed Medicaid plans in 2018.

TRULANCE IBS-C Development Update

All activities are progressing on-track to support the FDA review of the supplemental new drug application (sNDA) for TRULANCE for the treatment of adults with IBS-C. The Prescription Drug User Fee Act (PDUFA) date is January 24, 2018.

Financial Results

Total net sales were $5.0 million for the third quarter of 2017, a 117.4% increase over the prior quarter.Net cash used in operating activities were $59.3 million for the third quarter of 2017.For the third quarter of 2017, operating expenses included approximately $6.6 million in research and development (R&D) costs and $44.0 million in selling, general and administrative (SG&A) expenses.Synergy reported a net loss of $48.9 million, or $0.22 per share, for the third quarter of 2017.Cash and cash equivalents were approximately $117.8 million at the end of the quarter.In September 2017, Synergy entered into a senior secured term loan of up to $300.0 million. The Company borrowed $100.0 million at the time of closing. The Term Loan has a maturity date of June 30, 2025 and bears interest at a rate equal to 9.5% per annum, with quarterly, interest-only payments until June 30, 2022.

ziet er niet slecht uit (denk ik persoonlijk) in de ah handel steeg aandeel alleszins (2.97 naar 3.09)
exmar/pfizer,Fibrocel,Generalmoly,Caratherapeutics,Freeport,Tshrombo,MDx,Petrobras,ablynx,nyrstar,shakeshack,sarepta,,biocartis,teva,,echo -&synergy therapeutics,catalyst bioscience,fortress bio